Jpmorgan Chase & CO Bio Xcel Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 749 shares of BTAI stock, worth $479. This represents 0.0% of its overall portfolio holdings.

Number of Shares

749

Previous 8,936 91.62%

Holding current value

$479

Previous $25,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.14 - $2.97 $9,333 - $24,315	-8,187 Reduced 91.62%	749 $0
Q1 2024 May 10, 2024	SELL	$1.95 - $4.04 $7,345 - $15,218	-3,767 Reduced 29.65%	8,936 $25,000
Q4 2023 Feb 12, 2024	SELL	$2.32 - $5.51 $243 - $578	-105 Reduced 0.82%	12,703 $37,000
Q3 2023 Nov 14, 2023	SELL	$2.49 - $11.85 $21,493 - $102,289	-8,632 Reduced 40.26%	12,808 $32,000
Q2 2023 Aug 11, 2023	BUY	$6.39 - $28.58 $26,512 - $118,578	4,149 Added 24.0%	21,440 $142,000
Q1 2023 May 18, 2023	BUY	$17.7 - $33.24 $259,322 - $486,999	14,651 Added 554.96%	17,291 $322,000
Q1 2023 May 11, 2023	SELL	$17.7 - $33.24 $158,503 - $297,664	-8,955 Reduced 77.23%	2,640 $49,000
Q4 2022 Feb 13, 2023	BUY	$10.25 - $22.43 $10,311 - $22,564	1,006 Added 9.5%	11,595 $249,000
Q3 2022 Nov 14, 2022	BUY	$11.19 - $17.89 $2,361 - $3,774	211 Added 2.03%	10,589 $126,000
Q2 2022 Aug 11, 2022	SELL	$9.03 - $21.55 $29,148 - $69,563	-3,228 Reduced 23.72%	10,378 $137,000
Q1 2022 May 11, 2022	BUY	$15.0 - $22.83 $28,050 - $42,692	1,870 Added 15.93%	13,606 $284,000
Q4 2021 Feb 10, 2022	BUY	$20.12 - $35.09 $15,753 - $27,475	783 Added 7.15%	11,736 $238,000
Q3 2021 Nov 12, 2021	BUY	$23.84 - $32.03 $261,119 - $350,824	10,953 New	10,953 $332,000

Others Institutions Holding BTAI

# of Institutions

Shares Held

7.2M

Call Options Held

101K

Put Options Held

205K

View Full List

About BioXcel Therapeutics, Inc.

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $17.9M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

More about BTAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Bio Xcel Therapeutics, Inc. Transaction History